NK3R Inhibitors
2 drugsAbout NK3R
The neurokinin-3 receptor (NK3R) is a G protein-coupled receptor (GPCR) involved in various physiological processes. As a GPCR, it modulates intracellular signaling pathways upon activation by its cognate ligand.
NK3R has emerged as a therapeutic target, evidenced by the FDA approval of two drugs, VEOZAH and LYNKUET. Currently, there is no genetic evidence directly linking NK3R to specific diseases.
Two small molecule drugs, LYNKUET (Bayer) and VEOZAH (ASTELLAS), target NK3R for other therapeutic areas. These approvals highlight the druggability of NK3R and its potential for therapeutic modulation.
Top NK3R Drugs
ASTELLAS and Bayer are the only two companies with approved drugs targeting NK3R.
Limited competition suggests an opportunity for new entrants, but also highlights potential market entry barriers.
NK3R Drug Modality Landscape
Modalities
Routes of Administration
NK3R is amenable to small molecule drugs, with oral options available for convenient dosing.
Explore alternative modalities like antibodies or peptides to expand the therapeutic options for NK3R.
NK3R Clinical Trials 46 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on NK3R. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 18 | 16 | 0 | 2 | 100% |
| Phase 2 | 13 | 6 | 1 | 6 | 86% |
| Phase 3 | 15 | 11 | 0 | 4 | 100% |
Top Sponsors
By Modality
Top Conditions
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved NK3R drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting NK3R. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
NK3R Drug Approval Timeline (2023 - 2025)
The first NK3R-targeting drug was approved in 2023, with the most recent approval in 2025.
Recent approvals indicate growing interest in NK3R, but further approvals may saturate the current therapeutic area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 13 (5 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on NK3R. A trial counts if an approved drug acting on NK3R is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.